Home/Vandria/Klaus Dugi, MD

KD

Klaus Dugi, MD

Chief Executive Officer

Therapeutic Areas

CNS Musculoskeletal Pulmonary Hepatic

Vandria Pipeline

Drug	Indication	Phase
VNA-318	Cognitive Impairment (Alzheimer's Disease, Major Depressive Disorder)	Phase 1

Leadership Team at Vandria

Pénélope Andreux, PharmD, PhD

Chief Scientific Officer

Peter Harboe-Schmidt, MSc, MBA

Head BD & Finance

Leila Mirmohamadsadeghi, PhD

Director Preclinical Operations

Chief Medical Officer

View full Vandria profile